Since the compound is intended for topical use in psoriasis, where DMF has been shown to be harmful, and CES2 expression was previously observed in keratinocytes [107], the authors subjected both DMF and the new compound to in vitro test-tube incubation with CES2. Here, CES2 is linked to psoriasis.